Your browser doesn't support javascript.
Cross-reactive Antibody Response to mRNA SARS-CoV-2 Vaccine After Recent COVID-19-Specific Monoclonal Antibody Therapy.
Schultz-Cherry, Stacey; McGargill, Maureen A; Thomas, Paul G; Estepp, Jeremie H; Gaur, Aditya H; Allen, E Kaitlynn; Allison, Kim J; Tang, Li; Webby, Richard J; Cherry, Sean D; Lin, Chun-Yang; Fabrizio, Thomas; Tuomanen, Elaine I; Wolf, Joshua.
  • Schultz-Cherry S; Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • McGargill MA; Department of Immunology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • Thomas PG; Department of Immunology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • Estepp JH; Department of Global Pediatric Medicine, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • Gaur AH; Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • Allen EK; Department of Immunology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • Allison KJ; Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • Tang L; Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • Webby RJ; Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • Cherry SD; Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • Lin CY; Department of Global Pediatric Medicine, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • Fabrizio T; Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • Tuomanen EI; Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • Wolf J; Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Open Forum Infect Dis ; 8(9): ofab420, 2021 Sep.
Article in English | MEDLINE | ID: covidwho-1437840
ABSTRACT
The efficacy of coronavirus disease 2019 (COVID-19) vaccines administered after COVID-19-specific monoclonal antibody is unknown, and "antibody interference" might hinder immune responses leading to vaccine failure. In an institutional review board-approved prospective study, we found that an individual who received mRNA COVID-19 vaccination <40 days after COVID-19-specific monoclonal antibody therapy for symptomatic COVID-19 had similar postvaccine antibody responses to SARS-CoV-2 receptor binding domain (RBD) for 4 important SARS-CoV-2 variants (B.1, B.1.1.7, B.1.351, and P.1) as other participants who were also vaccinated following COVID-19. Vaccination against COVID-19 shortly after COVID-19-specific monoclonal antibody can boost and expand antibody protection, questioning the need to delay vaccination in this setting. TRIAL REGISTRATION The St. Jude Tracking of Viral and Host Factors Associated with COVID-19 study; NCT04362995; https//clinicaltrials.gov/ct2/show/NCT04362995.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Observational study / Randomized controlled trials / Risk factors Language: English Journal: Open Forum Infect Dis Year: 2021 Document Type: Article Affiliation country: Ofid

Full text: Available Collection: International databases Database: MEDLINE Type of study: Observational study / Randomized controlled trials / Risk factors Language: English Journal: Open Forum Infect Dis Year: 2021 Document Type: Article Affiliation country: Ofid